News - Page 3 of 3 - Mitsui & Co. Global Investment, Inc.

RallyBio announces clinical proof of concept for RLYB211, an anti-HPA-1a antibody for the prevention of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT).

Rallybio, a clinical-stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders, today announced that clinical proof of concept has been established in the ongoing Phase 1/2 study of RLYB211.

News|Proterra

Proterra goes public on NASDAQ through SPAC (special purpose acquisition company) merger.

By Mswartz

Proterra Inc (“Proterra” or the “Company”), a leading innovator in commercial vehicle electrification technology, today announced that its shares of common stock and warrants will begin trading on the Nasdaq Global Select Market today under the new ticker symbols “PTRA” and “PTRAW,” respectively.

News|Svante

Svante receives $25M from the Government of Canada to support the commercialization and industrialization of their low-cost carbon capture technology.

By Mswartz

Svante Inc., announced that the Government of Canada made a CDN$25 million investment to support the industrialization and commercialization of its novel low-cost carbon capture technology within the North American market.

Cipia|News

Cipia and Intcomex partner to support increasing demand for fleet management and driver monitoring.

By Caroline Pinkney

Cipia, an AI computer vision in-cabin automotive solutions provider, and Intcomex, the leading platform for value-added solutions and technology products in Latin America and the Caribbean, today announced a partnership to meet the dramatically growing demand for video telematics and driver monitoring solutions in the LATAM commercial fleets market.